Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could your own tumor cells fight cancer? new trial tests immune cell therapy

NCT ID NCT03449108

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer, anaplastic thyroid cancer, and bone or soft tissue sarcomas that have not responded to other treatments. The goal is to see if this approach can shrink tumors and control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tumor-infiltrating lymphocytes (LN-145 or LN-145-S1) plus aldesleukin and chemotherapy

What this could lead to

If successful, this could offer a new treatment option for patients with hard-to-treat cancers like ovarian, triple-negative breast, and bone sarcomas.

What could go wrong

This is an early-phase trial with only 30 participants, so results may not apply broadly. Side effects from the cell therapy and chemotherapy can be severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone cancer bone giant cell tumor bone sarcoma cancer dedifferentiated chondrosarcoma malignancy in giant cell tumor of bone osteosarcoma ovarian cancer ovarian carcinoma ovarian carcinosarcoma poorly differentiated thyroid gland carcinoma sarcoma soft tissue sarcoma thyroid gland squamous cell carcinoma thyroid gland undifferentiated (anaplastic) carcinoma triple-negative breast carcinoma undifferentiated high grade pleomorphic sarcoma of bone undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE SARCOMA DEDIFFERENTIATED CHONDROSARCOMA GIANT CELL TUMOR OF BONE MALIGNANCY IN GIANT CELL TUMOR OF BONE MALIGNANT SOLID NEOPLASM OVARIAN CARCINOSARCOMA PLATINUM-RESISTANT OVARIAN CARCINOMA POORLY DIFFERENTIATED THYROID GLAND CARCINOMA RECURRENT OSTEOSARCOMA RECURRENT OVARIAN CARCINOMA REFRACTORY OSTEOSARCOMA SOFT TISSUE SARCOMA THYROID GLAND ANAPLASTIC CARCINOMA THYROID GLAND SQUAMOUS CELL CARCINOMA TRIPLE NEGATIVE BREAST CANCER UNDIFFERENTIATED HIGH GRADE PLEOMORPHIC SARCOMA OF BONE

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States